We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

119 hedge funds and large institutions have $637M invested in CytomX Therapeutics in 2017 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 47 increasing their positions, 24 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 12

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

96% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 24

45% more capital invested

Capital invested by funds: $441M → $637M (+$196M)

23% more funds holding

Funds holding: 97 → 119 (+22)

12.74% more ownership

Funds ownership: 65.75% → 78.49% (+13%)

58% less call options, than puts

Call options by funds: $21K | Put options by funds: $50K

Holders
119
Holders Change
+22
Holders Change %
+22.68%
% of All Funds
2.7%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
34
Increased
47
Reduced
24
Closed
12
Calls
$21K
Puts
$50K
Net Calls
-$29K
Net Calls Change
-$29K

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$22.8M
2
BlackRock
BlackRock
New York
+$12.2M
3
PAMU
Pictet Asset Management (UK)
United Kingdom
+$12.2M
4
Invesco
Invesco
Georgia
+$7.86M
5
State Street
State Street
Massachusetts
+$4.93M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$22.9M
2
EC
EcoR1 Capital
California
-$15.1M
3
OM
Opaleye Management
Massachusetts
-$8.18M
4
TCM
Tekla Capital Management
Massachusetts
-$5.5M
5
Deutsche Bank
Deutsche Bank
Germany
-$2.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAG
26
Private Advisor Group
New Jersey
$4.19M – – –
BIM
27
Bogle Investment Management
Massachusetts
$4.14M +$667K +32,180 +20%
PAM
28
Panagora Asset Management
Massachusetts
$3.96M +$1.28M +61,767 +49%
OAM
29
Oxford Asset Management
United Kingdom
$3.88M +$200K +9,654 +6%
NC
30
Nexthera Capital
New York
$3.8M +$3.73M +179,870 New
CC
31
Casdin Capital
New York
$3.75M – – –
Charles Schwab
32
Charles Schwab
California
$3.73M +$172K +8,279 +5%
SFM
33
Sphera Funds Management
Israel
$3.38M -$1.04M -50,000 -24%
Two Sigma Investments
34
Two Sigma Investments
New York
$3.24M +$342K +16,479 +12%
Wells Fargo
35
Wells Fargo
California
$3M +$1.68M +81,215 +134%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$2.74M +$9.43K +455 +0.4%
CPC
37
Congress Park Capital
New York
$2.66M +$2.61M +125,975 New
Two Sigma Advisers
38
Two Sigma Advisers
New York
$2.58M +$1.43M +69,200 +131%
Bank of America
39
Bank of America
North Carolina
$2.56M +$519K +25,041 +26%
Russell Investments Group
40
Russell Investments Group
United Kingdom
$2.38M +$1.91M +92,305 +598%
Morgan Stanley
41
Morgan Stanley
New York
$2.1M -$2M -96,338 -49%
AQR Capital Management
42
AQR Capital Management
Connecticut
$2.01M +$886K +42,751 +81%
GIM
43
Granahan Investment Management
Massachusetts
$1.92M +$1.89M +91,144 New
CS
44
Candriam SCA
Luxembourg
$1.88M -$1.58M -76,000 -46%
AllianceBernstein
45
AllianceBernstein
Tennessee
$1.73M +$172K +8,300 +11%
Schroder Investment Management Group
46
Schroder Investment Management Group
United Kingdom
$1.68M +$1.09M +52,348 +193%
IHM
47
Iguana Healthcare Management
New York
$1.58M +$104K +5,000 +7%
Deutsche Bank
48
Deutsche Bank
Germany
$1.51M -$2.63M -126,762 -64%
Federated Hermes
49
Federated Hermes
Pennsylvania
$1.46M +$1.44M +69,350 New
ACI
50
AMP Capital Investors
Australia
$1.41M +$543K +26,183 +65%
1
2
3 4 5

CTMX Hedge Fund Activity: Q4 2017 in Review

119 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2017, worth a combined $637M — up 45% from $441M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new CTMX positions and 12 closed out — a net gain of 22 holders — while 47 added to existing stakes and 24 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $22.8M. The largest seller was BVF Inc, cutting an estimated $22.9M.

  • 119 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2017, up from 97 in Q3 2017.
  • Funds reported $637M of CytomX Therapeutics stock for Q4 2017, up 45% quarter-over-quarter.
  • 34 funds opened new CytomX Therapeutics positions in Q4 2017 and 12 closed out, a net change of +22 holders.
  • The largest CytomX Therapeutics buyer in Q4 2017 was Perceptive Advisors, an estimated $22.8M added.
  • The largest CytomX Therapeutics seller in Q4 2017 was BVF Inc, an estimated $22.9M sold.

Based on aggregated 13F filings for Q4 2017.